A Review of FDA-Approved Multi-Target Angiogenesis Drugs for Brain Tumor Therapy
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26052192 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Iuliana Mihaela Buzatu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, "Fundeni" Clinical Institute, Șoseaua Fundeni 258, 022328 Bucharest, Romania. Hauptthemen laut MEDLINE: Brain Neoplasms, Angiogenesis Inhibitors, Neovascularization, Pathologic, Protein Kinase Inhibitors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 268 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Unitatea Executiva Pentru Finantarea Invatamantului Superior a Cercetarii Dezvoltarii si Inovarii, UEFISCDI, Bucharest.
Abstract (Originalsprache)
Neovascularization is an important process in brain tumor development, invasion and metastasis. Several research studies have indicated that the VEGF signaling target has potential for reducing angiogenesis in brain tumors. However, targeting VEGF signaling has not met the expected efficacy, despite initial enthusiasm. This is partly because tumors cleverly use alternative growth factor pathways, other than VEGF signaling, to restore angiogenesis. Multi-target inhibitors have been developed to inhibit several receptor kinases that play a role in the development of angiogenesis. By simultaneously affecting various receptor kinases, these treatments can potentially obstruct various angiogenic pathways that are involved in brain cancer advancement, often offering a more holistic strategy than treatments focusing on just one kinase. Since 2009, the FDA has approved a number of multi-kinase inhibitors that target angiogenic growth factor receptors (e.g., VEGFR, PDGFR, FGFR, RET, c-KIT, MET, AXL and others) for treatment of malignant diseases, including brain cancer. Here, we present some recent results from the literature regarding the preclinical and clinical effects of these inhibitors on brain tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, "Fundeni" Clinical Institute, Șoseaua Fundeni 258, 022328 Bucharest, Romania.
- Department of Neurosurgery, Clinical Emergency Hospital "Bagdasar-Arseni", Soseaua Berceni 12, 041915 Bucharest, Romania.
- Department of Neurosurgery, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania.
- Department of Biochemistry, Carol Davila University of Medicine and Pharmacy, 020022 Bucharest, Romania.
- Department of Neurology, University of Medicine and Pharmacy of Craiova, Petru Rares 2, 200349 Craiova, Romania.
ORCID-Profile: Ligia Gabriela Tataranu, Carmen Duta, Irina Stoian, Oana Alexandru
Förderung
- Unitatea Executiva Pentru Finantarea Invatamantului Superior a Cercetarii Dezvoltarii si Inovarii
- UEFISCDI, Bucharest
Zitieren
APA
Buzatu, I. M., Tataranu, L. G., Duta, C., Stoian, I., Alexandru, O., & Dricu, A. (2025). A Review of FDA-Approved Multi-Target Angiogenesis Drugs for Brain Tumor Therapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26052192
Vancouver
Buzatu IM, Tataranu LG, Duta C, Stoian I, Alexandru O, Dricu A. A Review of FDA-Approved Multi-Target Angiogenesis Drugs for Brain Tumor Therapy. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26052192
BibTeX
@article{Buzatu2025,
author = {Buzatu, Iuliana Mihaela and Tataranu, Ligia Gabriela and Duta, Carmen and Stoian, Irina and Alexandru, Oana and Dricu, Anica},
title = {A Review of FDA-Approved Multi-Target Angiogenesis Drugs for Brain Tumor Therapy},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26052192}
}
EUVIMED